High-dose crizotinib for brain metastases refractory to standard-dose crizotinib.
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Sakyo-Ku, Kyoto, Japan.
Young Hak
YH
Kim
Hiroaki
H
Ozasa
Hiroki
H
Nagai
Yuichi
Y
Sakamori
Hironori
H
Yoshida
Yoshitaka
Y
Yagi
Takashi
T
Nakaoku
Michiaki
M
Mishima
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000077547:Crizotinib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*
D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib